Research Site

Jacksonville Beach, Florida 32250

1 studies enrolling now · 12 studies all time

What they study most

ASCVD Management, Anemia, Anemia in Chronic Kidney Disease Patients Not on Dialysis, Cardiovascular Disease, Chronic Kidney Disease and Hypertension, Congestive Heart Failure, Cost Sharing, Acute Coronary Syndrome, Depression, Depressive Disorder, Depressive Disorder, Major, Diabetes Mellitus, Non-Insulin-Dependent, Dyslipidemia

Studies at this site

• A Phase III Renal Outcomes and Cardiovascular Mortality Study to Investigate the Efficacy and Safety of Baxdrostat in Combination With Dapagliflozin in Participants With Chronic Kidney Disease and High Blood Pressure — Recruiting now
• A Phase III Study to Investigate the Efficacy and Safety of Baxdrostat in Combination With Dapagliflozin on CKD Progression in Participants With CKD and High Blood Pressure. — Running, not enrolling
• Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk — Completed
• Getting to an Improved Understanding of Low-Density Lipoprotein Cholesterol and Dyslipidemia Management (GOULD) a Registry of High Cardiovascular Risk Subjects in the United States — Completed
• RED-HF™ Trial - Reduction of Events With Darbepoetin Alfa in Heart Failure Trial — Completed
• Strategies Using Darbepoetin Alfa to Avoid Transfusions in Chronic Kidney Disease — Completed
• Multicenter Trial to Evaluate the Effect of Dapagliflozin on the Incidence of Cardiovascular Events — Completed
• Affordability and Real-world Antiplatelet Treatment Effectiveness After Myocardial Infarction Study — Completed
• Safety and Tolerability of Oral OPC-34712 as Adjunctive Therapy in Adults With Major Depressive Disorder (the Orion Trial) — Completed
• JC Virus Antibody Study of Participants With Relapsing Forms of MS Receiving Treatment With Natalizumab — Completed
• Real-world Outcomes on Tecfidera (BG00012, Dimethyl Fumarate) Post-Tysabri (BG00002, Natalizumab) — Completed
• Study of the Safety and Efficacy of Two Fixed Doses of OPC-34712 as Adjunctive Therapy in the Treatment of Adults With Major Depressive Disorder (the Polaris Trial) — Completed